Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Formulation and Evaluation of Naproxen Sodium Loaded Invasomes for Topical Delivery

Author(s): Abbaraju Krishna Shailaja* and Uzma Afreen

Volume 12, Issue 1, 2022

Published on: 18 July, 2022

Page: [32 - 43] Pages: 12

DOI: 10.2174/2468187312666220513113117

Price: $65

conference banner
Abstract

Introduction: Naproxen sodium is a non-steroidal anti-inflammatory agent used in the treatment of rheumatoid arthritis and ankylosing spondylitis to relieve pain and inflammation. It mainly acts by inhibiting COX1 and COX2 receptors. By inhibiting the COX1 receptor, it causes severe gastric bleeding and peptic ulcer, and by inhibiting the COX2 receptor, it causes cardiovascular side effects. In order to avoid the adverse effects of naproxen, there is a need to develop a novel drug delivery system. So that invasomes, because of their vesicular structure, are capable of penetrating more into the systemic circulation and will be acting locally and systemically.

Methods: In this study, attempts have been made to prepare and characterize naproxen sodium loaded invasomes. Naproxen sodium loaded invasomes were prepared by thin film hydration technique using soya lecithin as lipid, span60 as surfactant, limonene as terpene and methanol, ethanol and chloroform as organic solvents. A total of twelve formulations (INV1-INV12) of invasomes were prepared, in which four formulations were prepared by varying drug to surfactant ratio and eight formulations were prepared by varying drug to lipid ratio.

Results and Discussions: All the formulations were evaluated for drug content, entrapment efficiency, particle size, zeta potential, and invitro drug release. Among the twelve formulations of invasomes, the INV2 formulation (1:1) ratio containing 40mg drug and 40mg surfactant (span60) was found to be the best formulation with a drug content of 96.62%, entrapment efficiency of 90.9%, zeta potential of -68.5mV, mean particle diameter of 572.4 nm, and invitro drug release of 91.6% in a time period of 12 hrs and followed the zero order kinetics with non fickian diffusion mechanism.

Conclusion: In this present study, naproxen sodium loaded invasomes were successfully prepared and evaluated.

Keywords: Soyalecithin, limonene, span60, invasomes, controlleddrug delivery system, transdermal drug delivery system.

« Previous Next »
Graphical Abstract

[1]
Sultana SS, Shailaja A. Krishna. Preparation and evaluation of naproxen sodium loaded liposomes, ethosomes and transferosomes. J Biosci 2017; 11: 1-8.
[2]
Prasanthi D, Lakshmi PK. Vesicles-mechanism of transdermal permeation: A review. Asian J Pharm Clin Res 2012; 5: 18-25.
[3]
El-Nabarawi MA, Shamma RN, Farouk F, Nasralla SM. Dapsone loaded invasomes as a potential treatment of acne. AAPS PharmSciTech 2018; 19(5): 2174-84.
[http://dx.doi.org/10.1208/s12249-018-1025-0] [PMID: 29725903]
[4]
Buchiraju Ravi. Vesicular drug delivery system-An over view. Res J Pharm Biol Chem Sci 2017.
[5]
Bhanjare L, Ghillare N. development of biocompatible nanoparticles for sustained topical delivery of Rutin. Inter J Pharm Biochem Archiv 2012; 3(2): 326-32.
[6]
PranayaRagini B, Krishna Sailaja A. Preparation of aspirin loaded nanoparticles by nanoprecipitation technique. SOJ Pharm Pharmaceut Sci 2019; 6(2): 1-3.
[7]
Lakshmi PK, Kalpana B, Prasanthi D. Invasomes-novel vesicular carriers for enhanced skin permeation. Syst Rev Pharm 2014; 4(1): 26-30.
[8]
Saudagar RB, Bornare AS. Invasomes novel vesicular carriers for transdermal drug delivery. Inter J Univ Pharm Bio Sci Rev 2016; 5(6): 109-17.
[9]
Babaie S, Bakhshayesh ARD, Ha JW, Hamishehkar H, Kim KH. Invasome: A novel nanocarrier for transdermal drug delivery. Nanomaterials (Basel) 2020; 10(2): 1-12.
[http://dx.doi.org/10.3390/nano10020341] [PMID: 32079276]
[10]
Aqil M, Ahad A, Sultana Y, Ali A. Status of terpenes as skin penetration enhancers. Drug Discov Today 2007; 12(23-24): 1061-7.
[http://dx.doi.org/10.1016/j.drudis.2007.09.001] [PMID: 18061886]
[11]
Kalpana B, Lakshmi PK. Transdermal permeation enhancement of tolterodine tartarate through invasomes and iontophoresis. Scholar Res Libr 2013; 5(6): 119-26.
[12]
Lakshmi PK, Mounica V. Preparation and evaluation of curcumin invasomes. Inter J Drug Deliv Res 2014; 6(2): 113-20.
[13]
Vidya K, Lakshmi PK. Cytotoxic effect of transdermal invasomal anastrozole gel on MCF-7 breast cancer cell line. J Appl Pharm Sci Rev 2019; 9(3): 50-8.
[14]
Prasanthi D, Lakshmi PK. Iontophoretic transdermal delivery of finasteride in vesicular invasomal carriers. Pharm Nanotechnol 2013; 1: 136-50.
[http://dx.doi.org/10.2174/2211738511301020009]
[15]
Chen M, Liu X, Fahr A. Skin delivery of ferulic acid from different vesicular systems. J Biomed Nanotechnol 2010; 6(5): 577-85.
[http://dx.doi.org/10.1166/jbn.2010.1154] [PMID: 21329050]
[16]
Badran MM, Kuntsche J, Fahr A. Skin penetration enhancement by a microneedle device (Dermaroller) in vitro: Dependency on needle size and applied formulation. Eur J Pharm Sci 2009; 36(4-5): 511-23.
[http://dx.doi.org/10.1016/j.ejps.2008.12.008] [PMID: 19146954]
[17]
Enma V, Espinosa Paez, Murad John P, et al. Aspirin: Pharmacology and clinical applications. Thrombosis 2011; 2012
[18]
Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110(5-6): 255-8.
[http://dx.doi.org/10.1016/S0049-3848(03)00379-7] [PMID: 14592543]
[19]
Koester MC. An overview of the physiology and pharmacology of aspirin and nonsteroidal anti-inflammatory drugs. J Athl Train 1993; 28(3): 252-9.
[PMID: 16558240]

Rights & Permissions Print Cite
Article Metrics
4
© 2024 Bentham Science Publishers | Privacy Policy